HeartVue 6S seeks USA marketing

Pegasus/Heartview LLC has announced that clinical studies of its HeartVue 6S Heart Screening System - which obtained CE Mark Approval in Europe almost two years ago - have been completed according to FDA guidelines, as a pre-marketing condition for release in the USA.

The HeartVue 6S Screening System, use as a screening tool, provides a quick, accurate assessment of patients with suspected coronary artery disease in 1–2 minutes.
The clinical studies included testing 170 patients of various ages, genders, races, weights and health conditions. The results will now be analysed, interpreted and presented to the FDA in the form of a 510K Filing.


Read all latest stories

Related articles


News • Heart attacks, heart failure, stroke

COVID-19’s cardiovascular complications

COVID-19 can cause serious cardiovascular complications including heart failure, heart attacks and blood clots that can lead to strokes, emergency medicine doctors at the University of Virgina report…


Article • Mobile cMyC analysis

The future POCT heart attack test

Experts report that a new blood test to diagnose heart attacks could be carried out on a hand-held device in the not-too-distant future. The test, devised by a team at Kings College London, uses…


News • Defibrillator use

Italian law must change to improve survival from cardiac arrest

An Italian law requiring citizens to hold a certificate to use a defibrillator must change to improve survival from cardiac arrest, researchers argued today at Acute Cardiovascular Care 2018, a…

Related products

Subscribe to Newsletter